Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer.
Figg
W D
WD
Pharmacology Branch, National Cancer Institute, Bethesda, Maryland, USA.
Sartor
O
O
Cooper
M R
MR
Thibault
A
A
Bergan
R C
RC
Dawson
N
N
Reed
E
E
Myers
C E
CE
D000368:Aged; D000728:Androgens / Q000819:agonists*; D005485:Flutamide / Q000008:administration & dosage / Q000494:pharmacology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D017430:Prostate-Specific Antigen / Q000097:blood / Q000187:drug effects*; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000276:immunology* / Q000378:metabolism / Q000473:pathology; D011944:Receptors, Androgen / Q000187:drug effects*; D016896:Treatment Outcome
D000728:Androgens; D011944:Receptors, Androgen; D005485:Flutamide; D017430:Prostate-Specific Antigen